Kinase News and Research

RSS

Scientists identify genes that act in muscles to modulate aging and resistance to stress

Researchers at Emory University School of Medicine have identified a set of genes that act in muscles to modulate aging and resistance to stress in fruit flies.

18 Oct 2011

Janssen, BeiGene enter in-licensing agreement for two clinical-stage oncology compounds

BeiGene, Ltd., today announced that it has entered into exclusive in-licensing and co-development agreements with Janssen Pharmaceutica NV and its affiliates for two clinical-stage oncology compounds.

15 Oct 2011

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.

14 Oct 2011

NCCN Oncology Research Program wins two GSK grants

The National Comprehensive Cancer Network Oncology Research Program (ORP) has been awarded $4 million in the form of two research grants from GlaxoSmithKline (GSK) to develop studies to scientifically evaluate and define GSK2118436, a BRAF inhibitor, and GSK1120212, a MEK1 and MEK2 inhibitor. Previous research has indicated that BRAF mutations are strong targets for therapies in the treatment of advanced melanoma.

12 Oct 2011

Receptor tyrosine kinases control PI3K signaling in human KRAS mutant colorectal cancers

Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers - combine them with inhibitors of the MEK/ERK signaling pathway.

11 Oct 2011

Creabilis receives $20 million in Series B funding

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, inflammation and pain, has raised €15 million ($20 million) in a Series B funding round led by Abbott Biotech Ventures.

4 Oct 2011

La Jolla Institute scientist identifies previously unknown T cell interaction

Most of the time, the immune system is the body's protector, warding off invading viruses and bacteria before they can lead to infection and disease. But in autoimmune diseases, the immune system does an about face, turning on the body and attacking normal cells.

3 Oct 2011

Researchers discover new inherited disorder that causes mental retardation, liver dysfunction

Researchers at the Swedish medical university Karolinska Institutet have discovered a new inherited disorder that causes severe mental retardation and liver dysfunction. The disease, adenosine kinase deficiency, is caused by mutations in the ADK gene, which codes for the enzyme adenosine kinase.

1 Oct 2011

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

The work of a team of scientists at Cold Spring Harbor Laboratory (CSHL) led by Professor Nicholas Tonks FRS, suggests a way to overcome one of the major technical obstacles preventing a leading therapeutic target for diabetes and obesity from being addressed successfully by novel drugs.

30 Sep 2011

Fat-rich 'western diet' fuels cardiovascular disease, type 2 diabetes and obesity

A major risk factor for cardiovascular disease, type 2 diabetes and other health- and life-threatening conditions, obesity is epidemic in the United States and other developed nations where it's fueled in large part by excessive consumption of a fat-rich "Western diet."

30 Sep 2011

ALK gene discovered by St. Jude scientists associated with FDA approved adult cancer drug

A drug recently approved by the U.S. Food and Drug Administration for treatment of an adult cancer targets a malfunctioning gene discovered more than a decade earlier at St. Jude Children's Research Hospital. The story highlights how scientific findings from St. Jude can be translated into therapies and tests that in addition to helping children, also help adults.

30 Sep 2011

Scientists discover effective target to kill late-stage metastatic prostate cancer cells

Purdue University scientists believe they have found an effective target for killing late-stage, metastatic prostate cancer cells.

29 Sep 2011

Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has completed enrollment for its Phase II clinical trial of Archexin in metastatic pancreatic cancer.

29 Sep 2011

Scientists identify proteasome phosphatase that appears to regulate removal of damaged proteins

A study by scientists at the University of California, San Diego and UC Irvine has identified an enzyme called a proteasome phosphatase that appears to regulate removal of damaged proteins from a cell. The understanding of how this process works could have important implications for numerous diseases, including cancer and Parkinson's disease.

28 Sep 2011

Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program

Afraxis, a San Diego-based biotechnology company developing drugs to treat rare genetic diseases through the modulation of p21-activated kinase (PAK), announced today that it has been selected to participate in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Disease (TRND) Program.

27 Sep 2011

Cyclin E plays a crucial role in the formation of nerve connections

Scientists at Dana-Farber Cancer Institute and Harvard Medical School have found that a common cancer protein leads a second, totally different life in normal adult brain cells: It helps regulates memory formation and may be implicated in Alzheimer's disease.

23 Sep 2011

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as lymphomas and neuroblastoma.

22 Sep 2011

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

Study reveals possible new treatment targets for diffuse intrinsic pontine gliomas

Study led by St. Jude Children's Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies.

21 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

Kinase News and Research

Scientists identify genes that act in muscles to modulate aging and resistance to stress

Janssen, BeiGene enter in-licensing agreement for two clinical-stage oncology compounds

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

NCCN Oncology Research Program wins two GSK grants

Receptor tyrosine kinases control PI3K signaling in human KRAS mutant colorectal cancers

Creabilis receives $20 million in Series B funding

La Jolla Institute scientist identifies previously unknown T cell interaction

Researchers discover new inherited disorder that causes mental retardation, liver dysfunction

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

Fat-rich 'western diet' fuels cardiovascular disease, type 2 diabetes and obesity

ALK gene discovered by St. Jude scientists associated with FDA approved adult cancer drug

Scientists discover effective target to kill late-stage metastatic prostate cancer cells

Enrollment complete in Rexahn's Archexin Phase II trial for metastatic pancreatic cancer

Scientists identify proteasome phosphatase that appears to regulate removal of damaged proteins

Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program

Cyclin E plays a crucial role in the formation of nerve connections

Virginia G. Piper, TGen and Scottsdale Healthcare begin AP26113 Phase 1 study in NSCLC

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Study reveals possible new treatment targets for diffuse intrinsic pontine gliomas

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News